Why Guardant Health Stock Was the Picture of Health Today
There's nothing like free publicity to help goose the sales of a relatively new product.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
29.73 | |
29.37 | |
- | |
30.1799 | |
29.09 | |
15.81-37.0399 | |
3 673 M | |
124 M | |
692 M | |
-0.88 | |
1.106 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
There's nothing like free publicity to help goose the sales of a relatively new product.
Key Insights Guardant Health's estimated fair value is US$36.20 based on 2 Stage Free Cash Flow to Equity Guardant Health is estimated to be 43% undervalued based on current share price of US$20.68 A...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: